GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Desvenlafaxine (Pristiq)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

PRISTIQ: source applicability and renal evidence limits

No supplemental post-dialysis dose. The RX mirror is not independent corroboration of the matched label.

Before applying: Swallow ER tablets whole; taper rather than abruptly discontinue.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Historical source

Original GlobalRPh source

Product / population
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source
Source revision
Historical source; revision not established here
Retrieved
2026-09-05 (not the revision date)

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

Usual Dosing (Adults)

PRISTIQ is an SNRI for major depressive disorder. Recommended initial dose: 50 mg once daily with or without food, at approximately the same time each day. Studies found 50 to 400 mg/day effective, but no extra benefit above 50 mg/day, with more adverse events and discontinuations at higher doses. Taper gradually when possible to minimize discontinuation symptoms. Swallow tablets whole with fluid; do not divide, crush, chew or dissolve.

Renal Dosing

The source specifies 24-hour creatinine clearance: mild (50 to 80 mL/min), no adjustment; moderate (30 to 50), 50 mg/day; severe (<30) or ESRD, 50 mg every other day. Do not escalate doses in moderate/severe impairment or ESRD. Do not give supplemental doses after dialysis.

Hemodialysis

ESRD: 50 mg every other day. No supplemental postdialysis dose. Do not escalate.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/desvenlafaxine/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

PRISTIQ: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

PRISTIQ: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

PRISTIQ: selected primary-label renal guidance and limits

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

No supplemental post-dialysis dose.

Dialysis evidence: A regimen is reported in selected content

Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Renal method: Cockcroft-Gault CrCl, mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

PRISTIQ: selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

No supplemental post-dialysis dose.

Dialysis evidence: A regimen is reported in selected content

Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Renal method: Cockcroft-Gault CrCl, mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

PRISTIQ: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

PRISTIQ: selected primary-label renal guidance and limits

Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Method: Cockcroft-Gault CrCl, mL/min

Read this complete source summary
Rxlist source

PRISTIQ: selected RX renal passage

Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Method: Cockcroft-Gault CrCl, mL/min

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePRISTIQ: selected primary-label renal guidance and limitsPRISTIQ: selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/desvenlafaxine/

Usual Dosing (Adults)

PRISTIQ is an SNRI for major depressive disorder. Recommended initial dose: 50 mg once daily with or without food, at approximately the same time each day. Studies found 50 to 400 mg/day effective, but no extra benefit above 50 mg/day, with more adverse events and discontinuations at higher doses. Taper gradually when possible to minimize discontinuation symptoms. Swallow tablets whole with fluid; do not divide, crush, chew or dissolve.

GRPH-desvenlafaxine-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

The source specifies 24-hour creatinine clearance: mild (50 to 80 mL/min), no adjustment; moderate (30 to 50), 50 mg/day; severe (<30) or ESRD, 50 mg every other day. Do not escalate doses in moderate/severe impairment or ESRD. Do not give supplemental doses after dialysis.

GRPH-desvenlafaxine-02 · Source section: Renal DosingRenal section finder

Hemodialysis

ESRD: 50 mg every other day. No supplemental postdialysis dose. Do not escalate.

GRPH-desvenlafaxine-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

PRISTIQ: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Renal method: Cockcroft-Gault CrCl, mL/min
Source date: Revision date not captured in selected review; retrieval date is not revision date.
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

No supplemental post-dialysis dose.

Dialysis evidence: A regimen is reported in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 2.2; sections 2.1 and 2.5

Limits that apply to these rows

Read the complete source-specific limitations above and below this table. No patient dose is calculated.

Source-specific renal instructions
CrCl (mL/min)Maximum dose
30-5050 mg once daily
15-29 or ESRD <1525 mg daily OR 50 mg every other day
After dialysisNo supplemental dose
Read the retained text before reformatting

At CrCl 30-50 mL/min, the maximum is 50 mg daily. At CrCl 15-29 or ESRD below 15, the maximum is 25 mg daily or 50 mg every other day. Do not give supplemental doses after dialysis. These are renal maximums, not instructions to escalate. Taper when discontinuing and retain the full antidepressant safety and interaction review.

RDM72-desvenlafaxine-label-1 · Source locator: Section 2.2; sections 2.1 and 2.5

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f43610c-f290-46ea-d186-4f998ed99fce
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl, mL/min
Source date/version
Revision date not captured in selected review; retrieval date is not revision date.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
ab2b5eb57a6f81abd60ee738d558b419255cbc1adb83a6ce95da98f0e2e0d403
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

PRISTIQ: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Renal method: Cockcroft-Gault CrCl, mL/min
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

No supplemental post-dialysis dose.

Dialysis evidence: A regimen is reported in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 2.2; sections 2.1 and 2.5

The mirror gives the same renal maximums and explicitly advises against supplemental post-dialysis doses. The extended-release product should not be split to manufacture a lower dose.

RDM72-desvenlafaxine-rx-1 · Source locator: Section 2.2; sections 2.1 and 2.5

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/pristiq-drug/
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl, mL/min
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
8f138abf810a90ac9acd5f649da11f3b2be9691841b42a2705366c323c5de473

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/desvenlafaxine/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
564487db88eb88c49d33c358fd9f7aec655fcfe4acabc2ba3041e9cde8c73a98
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top